INVO Bioscience (INVO Bioscience) Change In Working Capital : $0.15 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is INVO Bioscience Change In Working Capital?

INVO Bioscience's change in working capital for the quarter that ended in Mar. 2024 was $0.29 Mil.

INVO Bioscience's change in working capital for the fiscal year that ended in Dec. 2023 was $0.47 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

INVO Bioscience Change In Working Capital Historical Data

The historical data trend for INVO Bioscience's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INVO Bioscience Change In Working Capital Chart

INVO Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

2.95

-0.85

-3.61

1.48

0.47

INVO Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															0.61	-0.01	-0.65	0.53	0.29

INVO Bioscience Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.15 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

INVO Bioscience Change In Working Capital Related Terms

Thank you for viewing the detailed overview of INVO Bioscience's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

INVO Bioscience (INVO Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » INVO Bioscience Inc (NAS:INVO) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

5582 Broadcast Court, Sarasota, FL, USA, 34240

Website

https://www.invobio.com

INVO Bioscience Inc operates as a medical device company focused on the Assisted Reproductive Technology (ART) marketplace that is creating simplified, lower-cost treatments for patients diagnosed with infertility. The company has developed the INVOcell device and procedure, the first Intravaginal Culture (IVC) system granted FDA clearance in the United States used for the incubation of eggs and sperm during fertilization and early embryo development. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.

Executives

Trent D Davis	director	811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot	director	802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum	director	9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren	officer: Chief Financial Officer	110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell	director	61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina	director	5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal	director	INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody	director, officer: Medical Director	1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes	officer: Acting CFO and PFO	1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux	10 percent owner	8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff	director, officer: CEO/Chairman	109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr	officer: Chief Financial Officer	92 GOULD STREET, WAKEFIELD MA 01880